Evidence map›Paper›PMID 34720947›Full record

ArticleCase reports in oncology

Germline VHL Mutation Discovered in Association with EGFR-Positive Lung Cancer and Metachronous Hepatocellular Carcinoma: A Case Report.

Justin J Kuhlman, Quinn J Frier, Daniel Sumarriva, Matthew Oberley, Danielle Bolton, Ruby A Deveras

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Justin J KuhlmanDepartment of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Quinn J FrierDepartment of Internal Medicine, Prisma Health, Columbia, South Carolina, USA.
Daniel SumarrivaDepartment of Molecular Science, Caris Life Sciences, Phoenix, Arizona, USA.
Matthew OberleyDepartment of Hematopathology, Caris Life Sciences, Phoenix, Arizona, USA.
Danielle BoltonHereditary Risks and Genetics, Center for Oncology, Halifax Health, Daytona Beach, Florida, USA.
Ruby A DeverasDepartment of Medical Oncology and Hematology, Halifax Health, Daytona Beach, Florida, USA.
Caris Life Sciences (United States) · USHalifax Health Medical Center · USJacksonville College · USPrisma Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VHL is a tumor suppressor gene located on chromosome 3 that is classically associated with tumors of the eye and CNS, renal cell carcinoma, and pheochromocytoma. We describe what appears to be the first report of an association between a germline VHL mutation and non-small cell lung cancer and metachronous hepatocellular carcinoma (HCC). Our case involves a 63-year-old nonsmoking male who was initially diagnosed with EGFR mutation-positive metastatic nonsquamous, non-small cell lung adenocarcinoma, who subsequently developed HCC and squamous cell carcinoma of the femur despite first-line treatment with EGFR-blocking osimertinib. Caris molecular profiling unexpectedly identified a shared underlying VHL mutation in all 3 lesions. Genetic mapping through a machine learning-based tool called Genomic Prevalence Score (GPSai

Indexed as

Hepatocellular carcinomaLung adenocarcinomaOsimertinibSquamous cell carcinomaVon Hippel-Lindau

Identifiers

PMID34720947
PMCPMC8525297
OpenAlexW3199615049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.